ストックスクリーナーアプリを入手
71.99
6.83%
4.60
前日終値:
$67.39
開ける：
$67.83
24時間の取引高:
5.09M
Relative Volume:
6.20
時価総額：
$2.30B
収益：
-
当期純損益:
$-38.99M
株価収益率:
-24.02
EPS:
-2.9966
ネットキャッシュフロー:
$-24.94M
1週間 パフォーマンス:
+46.59%
1か月 パフォーマンス:
+60.01%
6か月 パフォーマンス:
+46.53%
1年 パフォーマンス:
+68.20%
1日の値動き範囲:
$66.90
$73.97
1週間の範囲:
$48.22
$73.97
52週間の値動き範囲:
$36.61
$73.97
Soleno Therapeutics Inc Stock (SLNO) Company Profile
名前
Soleno Therapeutics Inc
セクター
電話
650-213-8444
住所
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
SLNO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
71.99 | 2.30B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2024-12-02 | 繰り返されました | Robert W. Baird | Outperform |
| 2024-12-02 | 繰り返されました | Stifel | Buy |
| 2024-09-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-10 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-05 | 開始されました | Piper Sandler | Overweight |
| 2024-01-23 | 開始されました | Stifel | Buy |
| 2023-11-21 | 再開されました | Guggenheim | Buy |
| 2020-09-29 | 開始されました | Guggenheim | Buy |
| 2020-01-10 | 開始されました | Craig Hallum | Buy |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2018-02-13 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Soleno Therapeutics Inc (SLNO) 最新ニュース
Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday? - Yahoo Finance
Major Shareholder Sells Massive Stake in Soleno Therapeutics! - TipRanks
Vivo opportunity sells $124 million in Soleno Therapeutics stock - Investing.com
PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR - PR Newswire
Stifel raises Soleno stock target to $108 after FDA approval - Investing.com
Soleno Therapeutics price target raised to $108 from $74 at Stifel - TipRanks
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? - Insider Monkey
Soleno Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
FDA Greenlights Soleno Therapeutics’ VYKAT XR for PWS Hyperphagia - geneonline
Oppenheimer lifts Soleno Therapeutics stock target to $105 By Investing.com - Investing.com Canada
Soleno Therapeutics pulls in FDA nod for treatment for rare genetic disease - Mugglehead
Biotech Zooms Into Breakout Zone On Hard-Fought Approval - Investor's Business Daily
First Prader-Willi treatment Vykat XR FDA-approved: Soleno soars - BioWorld Online
Drugmaker Soleno Soars on Approval to Treat Never Ending Hunger - Bloomberg
Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval (SLNO) - Seeking Alpha
Soleno wins FDA approval for Prader-Willi hyperphagia treatment - Yahoo
Soleno Shares Are Up Today: What's Going On? - Benzinga
FDA Approves Soleno Therapeutics’ Vykat XR for Hyperphagia in Patients with Prader-Willi Syndrome - Pharmaceutical Executive
Baird Raises Soleno Therapeutics' Price Target to $102 From $72, Outperform Rating Maintained - Marketscreener.com
Soleno Therapeutics: A Breakthrough in Rare Disease Treatment - RagingBull
Soleno’s Vykat Gains First Prader-Willi Syndrome Approval, Rivals To Follow - News & Insights
Soleno stock skyrockets on FDA drug approval - Yahoo Finance
Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - FiercePharma
Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - MSN
Soleno Therapeutics execs reap stock windfall after FDA approves rare disease drugSan Francisco Business Times - The Business Journals
Piper Sandler maintains $93 target on Soleno Therapeutics stock By Investing.com - Investing.com South Africa
Soleno Skyrockets 40% on FDA Nod for VYKAT XR - Wall Street Pit
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Benzinga
Stifel maintains Soleno Therapeutics buy rating post FDA nod By Investing.com - Investing.com Australia
Behind the Scenes of Soleno Therapeutics's Latest Options Trends - Benzinga
SLNO stock touches 52-week high at $66.16 amid robust growth - Investing.com India
Stifel maintains Soleno Therapeutics buy rating post FDA nod - Investing.com India
Piper Sandler maintains $93 target on Soleno Therapeutics stock - Investing.com India
Cantor Fitzgerald lifts Soleno Therapeutics stock target to $123 By Investing.com - Investing.com Australia
Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks - MSN
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - Yahoo Finance
Oppenheimer lifts Soleno Therapeutics stock target to $105 - Investing.com
Cantor Fitzgerald lifts Soleno Therapeutics stock target to $123 - Investing.com India
FDA approves Soleno’s Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome - PMLiVE
Why Is Soleno Therapeutics Soaring On Thursday?Soleno Therapeutics (NASDAQ:SLNO) - Benzinga
Soleno stock price target raised to $102 by Baird - Investing.com India
Stifel maintains Soleno Therapeutics buy rating, $74 target - Investing.com India
Soleno shares surge on FDA approval of Vykat for Prader-Willi syndrome - Investing.com
Soleno shares surge on FDA approval of Vykat for Prader-Willi syndrome By Investing.com - Investing.com South Africa
Soleno gains as US FDA approves its drug to treat rare genetic disorder - TradingView
Soleno Stock (SLNO) Soars 32% after FDA Greenlights New Drug - TipRanks
Soleno jumps 33% on drug approved to treat hyperphagia in Prader-Willi syndrome. - Seeking Alpha
US FDA approves first treatment for rare genetic disorder Prader-Willi syndrome - Marketscreener.com
Soleno Therapeutics’ ‘life-changing’ rare-disease drug approved - STAT
Soleno Therapeutics Secures FDA Approval for Drug to Treat Hyperphagia - Marketscreener.com
Soleno's Prader-Willi treatment gets FDA OK to treat hyperphagia - FirstWord Pharma
Soleno Therapeutics Inc (SLNO) 財務データ
収益
当期純利益
現金流量
EPS
Soleno Therapeutics Inc (SLNO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Vivo Opportunity, LLC | 10% Owner |
Mar 26 '25 |
Sale |
65.80 |
400,000 |
26,320,000 |
5,891,851 |
| Vivo Opportunity, LLC | 10% Owner |
Mar 28 '25 |
Sale |
70.60 |
333,557 |
23,549,124 |
4,458,294 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):